GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Long-Term Debt

Access Bio (XKRX:950130) Long-Term Debt : ₩14,630 Mil (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio Long-Term Debt?

Access Bio's Long-Term Debt for the quarter that ended in Jun. 2024 was ₩14,630 Mil.

Access Bio's quarterly Long-Term Debt declined from Dec. 2023 (₩14,690 Mil) to Mar. 2024 (₩14,660 Mil) and declined from Mar. 2024 (₩14,660 Mil) to Jun. 2024 (₩14,630 Mil).

Access Bio's annual Long-Term Debt increased from Dec. 2021 (₩0 Mil) to Dec. 2022 (₩14,810 Mil) but then declined from Dec. 2022 (₩14,810 Mil) to Dec. 2023 (₩14,690 Mil).

Access Bio Long-Term Debt Historical Data

The historical data trend for Access Bio's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Long-Term Debt Chart

Access Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21,557.11 152.77 - 14,810.00 14,690.00

Access Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,750.00 14,720.00 14,690.00 14,660.00 14,630.00

Access Bio  (XKRX:950130) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Access Bio Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Access Bio's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Access Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Long-Term Debt
Comparable Companies
XKRX:461030 XKRX:084650 XKRX:038290 XKRX:217330 XKRX:180400 XKRX:253840 XKRX:384470 XKRX:950200 XKRX:109820 XKRX:153710 TMO DHR XSWX:LONN IQV A IDXX MTD ICLR ILMN WAT
Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Website
http://www.accessbio.net
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines